口服乌帕替尼片评估中国青少年和成人特应性皮炎受试者的不良事件和疾病活动变化的真实世界研究
一项前瞻性、多中心、上市后观察性研究,旨在评估 Upadacitinib 在中国青少年和成人中重度特应性皮炎 (AD) 患者中的安全性和有效性
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants.
Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
研究概览
地位
条件
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100191
- Peking University Third Hospital /ID# 257722
-
-
Fujian
-
Fuzhou、Fujian、中国、350005
- The First Affiliated Hospital Of Fujian Medical University /ID# 257725
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510091
- Dermatology Hospital of Southern Medical University /ID# 261862
-
Shenzhen、Guangdong、中国、518033
- The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737
-
-
Henan
-
Zhengzhou、Henan、中国、450003
- People's Hospital of Henan Province /ID# 257736
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724
-
-
Liaoning
-
Shenyang、Liaoning、中国、110001
- First Affiliated Hospital of China Medical University /ID# 257641
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710004
- Second Affiliated Hospital of Xian Jiaotong University /ID# 257733
-
-
Shandong
-
Jinan、Shandong、中国、250022
- Shandong Dermatological Hospital /ID# 257727
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200040
- Huashan Hospital, Fudan University /ID# 256456
-
Shanghai、Shanghai Municipality、中国、200065
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726
-
Shanghai、Shanghai Municipality、中国、200443
- Shanghai Skin Disease Hospital /ID# 257719
-
-
Sichuan
-
Chengdu、Sichuan、中国、610017
- Chengdu Second Municipal People's Hospital /ID# 257732
-
Chengdu、Sichuan、中国、610041
- West China Hospital, Sichuan University /ID# 257720
-
Chengdu、Sichuan、中国、610072
- Sichuan Provincial People's Hospital /ID# 263898
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- Hangzhou First People's Hospital /ID# 261867
-
Hangzhou、Zhejiang、中国、310009
- The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723
-
Ningbo、Zhejiang、中国、315010
- Ningbo First Hospital /ID# 263884
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
描述
Inclusion Criteria:
- Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment.
- Chinese adolescents (≥12 to <18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment.
- Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label.
- The decision to prescribe Upadacitinib is made prior to and independently of study participation.
Exclusion Criteria:
- Participants who cannot be treated with Upadacitinib as per China label or by judgement of treating physician.
- Currently participating in any interventional research studies.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Upadacitinib
Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Incidence of Serious Infections
大体时间:Up to approximately 25 months
|
Incidence rate of serious infections in AD participants treated with Upadacitinib will be assessed. |
Up to approximately 25 months
|
合作者和调查者
赞助
调查人员
- 研究主任:ABBVIE INC.、AbbVie
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.